Ferredoxins are required to supply electrons to the cytochrome P450 enzymes involved in cross-linking reactions during the biosynthesis of the glycopeptide antibiotics balhimycin and vancomycin. However, the biosynthetic gene clusters for these antibiotics contain no ferredoxin-or ferredoxin reductase-like genes. In a search for potential ferredoxin partners for these P450s, we report here an in silico analysis of the draft genome sequence of the balhimycin producer Amycolatopsis balhimycina, which revealed 11 putative Fe-S-containing ferredoxin genes. We show that two members (balFd-V and balFd-VII), produced as native-like holo-[3Fe-4S] ferredoxins in E. coli, could supply electrons to the P450 OxyB (CYP165B) from both A. balhimycina and the vancomycin producer A. orientalis, and support in vitro turnover of peptidyl carrier protein-bound peptide substrates into monocyclic cross-linked products. These results show that ferredoxins encoded in the antibiotic-producing strain can act in a degenerate manner in supporting the catalytic functions of glycopeptide biosynthetic P450 enzymes from the same as well as heterologous gene clusters. 
Introduction
Cytochrome P450 enzymes typically catalyze the hydroxylation of substrates, using molecular oxygen and reducing equivalents supplied by NAD(P)H. The class I bacterial cytochrome P450 hydroxylases require a flavin-dependent ferredoxin reductase (FdR), which is reduced by NAD(P)H, and a ferredoxin (Fd) iron-sulfur protein to mediate electron transfer to the P450 heme . Less well studied is a small group of P450s that catalyze oxidative phenol coupling reactions on substrates containing phenolic groups (Isin & Guengerich, 2007) . Molecular oxygen is again required, but no oxygen atom is incorporated into the product of the enzymic reaction, although there is again a requirement for electrons, which must be shuttled from NAD(P)H to the heme during the catalytic cycle.
Three bacterial class I cytochrome P450 enzymes called OxyA, OxyB and OxyC catalyze three key cross-linking reactions in the biosynthesis of glycopeptide antibiotics of the vancomycin/balhimycin family ( Fig. 1 ). X-ray crystal structures of OxyB and OxyC from the vancomycin producer Amycolatopsis orientalis confirmed that each contains a typical P450 fold, with a conserved cysteine residue acting as proximal axial ligand for the heme (Pylypenko et al., 2003; Zerbe et al., 2002) . The order of the cross-linking reactions in balhimycin biosynthesis has been defined through gene inactivation experiments in A. balhimycina (Bischoff et al., 2005; Bischoff et al., 2001a; Bischoff et al., 2001b; Süssmuth et al., 1999) . The first cross-link, introduced by OxyB, is an aryl-ether bridge (C-O-D ring) between the side chains of residues-4 and -6. The second cross-link (D-O-E ring) is introduced by OxyA, and the final biaryl link (the AB ring) is created by OxyC. In vitro experiments have shown that linear hexa-or heptapeptides attached as C-terminal thioesters to the pantetheinyl group of a peptide carrier protein (PCP) domain from the glycopeptide non-ribosomal peptide synthetase (NRPS), are the preferred substrates for OxyB (Woithe et al., 2007; Zerbe et al., 2004) . The first cross-link, therefore, is introduced whilst the peptide chain of the antibiotic is still attached to the NRPS assembly line. So far, in vitro assays with the two remaining cross-linking enzymes OxyA and OxyC have not been reported, so the timing of these cross-linking steps remains undefined. One complicating factor for in vitro assays is that the natural electron transfer proteins for all three P450s have to date not been defined. The glycopeptide antibiotic gene clusters reported for balhimycin, chloroeremomycin, A40926, A47934 and teicoplanin, do not contain Fd or FdR genes (Donadio et al., 2005) . Only the biosynthetic gene cluster for the related natural product complestatin contains a single Fd gene (comK) (Chiu et al., 2001 ).
To advance in vitro studies of the cross-linking steps in glycopeptide antibiotic biosynthesis, we present efforts to identify and characterize Fd genes in the balhimycin producer A. balhimycina. The sequencing and annotation of the entire genome is currently underway. We describe in silico analyses, which reveal 11 different Fd genes in A.
balhimycina. Furthermore, we demonstrate the production and purification of two of the newly identified Fds, as well as their ability to participate in electron transfers to OxyB from both A. balhimycina and A. orientalis.
Materials and methods

Bioinformatic analyses
The A. balhimycina DSM5908 genome was analyzed using a BLAST search carried out with six Fd sequences (NP-631171, NP-629284, NP-631715, NP-625075, NP-628054, NP-625924) from S. coelicolor A3(2) (Chun et al., 2007; Lamb et al., 2002) , putidaredoxin (P00259) from P. putida (Peterson et al., 1990; Pochapsky et al., 1994; Sevrioukova et al., 2003) , and the putative ferredoxin comFd (AAK81833) from the complestatin producer S. lavendulae (Chiu et al., 2001) . 11 putative Fds, named balFd-I to balFd-XI, containing expect (E)-values lower than 10 -6 , were identified in the whole genome of A. balhimycina (Table 1) . Assignment of the iron-sulfur cluster type was achieved through a BLAST search of the non-redundant database and a comparison to known Fds. The sequences of the ferredoxins balFd-I -balFd-XI have been deposited in the EMBL database under the accession numbers FN594523-FN594533.
Cloning, expression and purification of recombinant A. balhimycina ferredoxins
The genomic DNA of A. balhimycina DSM5908 was used as a PCR template to amplify the genes coding for the putative [3Fe-4S] ferredoxins balFd-V and balFd-VII. The primers used are shown below (restriction sites underlined):
After digestion with NdeI and XhoI, the fragments were cloned between the NdeI / XhoI sites of plasmid pET22b (Novagen) for expression as C-terminal His 6 -tagged fusion proteins. The nt sequence of each insert was confirmed by sequencing.
For production in E. coli Rosetta2(DE3)pLysS (balFd-V) or Origami2(DE3) (balFd-VII), terrific broth medium (400 ml) supplemented with antibiotics and FeSO 4 (0.5 mM) was induced with isopropyl-β-D-thiogalactopyranoside (0.2 mM), and shaking at 30°C for 6 h.
Cell pellets in buffer-A (25 ml, 50 mM sodium phosphate pH 7.4, 300 mM KCl, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 0.05 % 2-mercaptoethanol, 5 % glycerol) were disrupted by sonication and the cell debris was removed by centrifugation. The supernatant was loaded onto a Ni-nitrilotriacetic acid (NTA) column (10 ml) in buffer-B (50 mM sodium phosphate, pH 7.4, 300 mM KCl, 20 mM imidazole).
After washing, C-terminal His 6 -tagged proteins were eluted with buffer-C (50 mM sodium phosphate, pH 7.4, 300 mM KCl, 300 mM imidazole The amounts of iron and acid labile sulfide per balFd-V and balFd-VII were determined following published procedures (Beinert, 1983; Fish, 1988) . The iron content was also determined by atomic adsorption spectroscopy (AAS).
Spinach Fd (spinFd), E. coli FdR (ecoFdR) and flavodoxin (ecoFld) were produced, following methods described earlier (Woithe et al., 2007) .
Production of P450s
The production and characterization of P450s followed methods described earlier (Woithe et al., 2007; Zerbe et al., 2002) . Each purified protein showed a single band of ca. 45 kDa by SDS-PAGE, and gave an electrospray MS spectrum consistent with the expected protein sequence minus the N-terminal methionine residue (data not shown). Furthermore, the UVVis spectrum of each P450 showed a Soret peak at 420±1 nm and α/ß bands around 569/537 nm.
CO-binding assays
Assays contained P450 (10 µM), NADPH (0.5 mM), glucose-6-phosphate (0.5 mM), glucose-6-phosphate dehydrogenase (0.5 U) in Tris-HCl buffer (50 mM, pH 7.5), with ecoFdR (20 µM) and one of: A, spinFd (10 µM); B, ecoFld (10 µM); C, balFd-V (10 µM); D, balFd-VII (10 µM)). The solution was divided between two cuvettes and CO was bubbled through the sample cuvette for 20 s. Difference spectra were recorded from 600 nm to 350 nm over 120 min.
Activity assays
Production and purification of apo-PCP, and the synthesis of peptide-PCP conjugates (1 and 2, Fig. 1 ), was as described previously (Woithe et al., 2007) . The assay, containing P450 (5 -10 µM), reduction system (Fd or ecoFld (10 µM), ecoFdR (20 µM)), NADPH (1 mM), glucose-6-phosphate (1 mM), glucose-6-phosphate dehydrogenase (0.5 U) and PCP-bound substrate (50 -100 µM) in Tris/HCl buffer (1 mL, 50 mM, pH 7.5), was incubated at 30°C
for 60 min. Protein was precipitated with 1/10 volume of trichloroacetic acid (TCA) (6 M) and the resulting pellet was resuspended in 400 µL Tris/HCl buffer (50 mM, pH 7.5) containing 2.5 % v/v hydrazine. After incubation at 30°C for 30 min the proteins were precipitated with TCA and separated from the supernatant containing the peptide hydrazides, which were analyzed by analytical reverse-phase HPLC (Agilent Zorbax Eclipse XDB (RP C18, 250 x 4.6 mm, 5 µM particle, 80 Å)) using a gradient of 5-40 % MeCN/0.1 % TFA in water/0.1 % TFA over 8 column volumes with a flow rate of 1 mL/min.
Results and Discussion
In silico analysis of A. balhimycina genome for ferredoxins within the same polypeptide chain (Meyer, 2008 griseus has been demonstrated with P450soy (Trower et al., 1990) . IV, -V, -VII and -VIII show high sequence homologies towards Fds that can either be found adjacent to a P450 monooxygenase in a biosynthetic gene cluster (NysM (Brautaset et al., 2000) , AmphM (Caffrey et al., 2001) and HbmFdx (Rascher et al., 2005) ), or which has been shown to co-purify with a P450 enzyme (Fd-2 from S. griseolus (O'Keefe et al., 1991) ).
These results suggest that the newly identified Fds might have a role in supporting the activity of P450 enzymes in A. balhimycina.
The balFd-X exhibits high sequence similarities toward [2Fe-2S] proteins (Table 1 and Fig. 2C ), in particular, Pdx from P. putida the natural redox partner of P450cam, with which it shares a sequence identity of 42% and contains the same four highly conserved cysteine residues involved in binding the FeS-cluster (Matsubara & Saeki, 1992) . The genomes of S. coelicolor A3(2) (Bentley et al., 2002) , S. avermitilis (Ikeda et al., 2003) , S.
griseus (Ohnishi et al., 2008) , M. tuberculosis (Cole et al., 1998) and Saccharopolyspora erythraea (Oliynyk et al., 2007) do not contain proteins with similarities to Pdx or balFd-X. 
Production and characterization of recombinant ferredoxins
The putative 7Fe The recombinant balFd-V and balFd-VII showed broad UV-Vis absorption maxima at 280-300 nm and 412 nm (Fig. 3) , 1991) . The quantitation of acid labile sulfide was also carried out using a colorimetric assay (Beinert, 1983) . Under optimized conditions, the assays gave 4.01±0.5 and 3.84±0.5 mol S per mol protein for balFd-V and balFd-VII, respectively.
Ferredoxin-mediated reduction of P450 heme iron
The OxyB P450 enzymes from the vancomycin biosynthetic gene cluster of A. orientalis (vanOxyB) and from the balhimycin biosynthetic gene cluster of A. balhimycina (balOxyB)
were used for CO-binding and activity assays. Upon reduction of the P450 heme iron from Fe(III) to Fe(II) using sodium dithionite and exposure to CO, both enzymes showed a characteristic Soret absorbance maximum at 450 nm. Following formation of the Fe(II)-CO complex, a new species is formed over 1-2 h, absorbing at about 420 nm, the so-called P420 form, which arises by protonation of the proximal cysteine thiolate ligand of the heme iron (Dunford et al., 2007; Perera et al., 2003) .
CO-binding assays were also performed with each P450 and the primary electron transfer proteins ecoFdR and one of spinFd, balFd-V, balFd-VII or ecoFld. These assays monitor the ability of each donor to transfer one electron to the P450 heme Fe(III) followed rapidly (<6 min) gave up to 75 % conversion (relative to dithionite) to the vanOxyB P450-form, whereas with ecoFld a maximum of 40 % conversion was reached only after 40 min. A fast formation of the P450 from vanOxyB (<10 min) was also observed using either Fd from
A. balhimycina, with 60 % conversion with balFd-V, and 45% with balFd-VII.
The OxyB enzymes from the balhimycin and vancomycin pathways share 88 % sequence identity. Nevertheless, some differences were observed between these enzymes in their abilities to accept electrons from the four primary redox partners. Thus, balOxyB and vanOxyB are both rapidly (<5-6 min) and efficiently (80%) converted into the P450 form by spinFd, but the emergence of the P450 form with balFd-V and balFd-VII was slower and reached at best 40% (balFd-V) and 20% (balFd-VII) of the response seen with sodium dithionite. With balOxyB essentially no reduction was observed using ecoFld.
These CO-binding assays do not inform whether or not a second electron transfer can occur to the heme as required in the full P450 catalytic cycle. For example, spinFd can donate the first electron to camphor-bound P450cam, but allows no hydroxylation of substrate (Lipscomb et al., 1976) . To address this point, assays were also carried out with peptide substrates of OxyB.
Ferredoxin-mediated catalytic activity
The assay for catalytic activity of OxyB is that described in earlier work Woithe et al., 2008; Woithe et al., 2007; Zerbe et al., 2004) . The substrates used are the model hexa-and heptapeptides 1 and 2 (Fig. 1) , which are closely related to the expected intermediates occurring during glycopeptide biosynthesis. Each peptide is covalently linked as a C-terminal thioester to an isolated recombinant PCP domain from the 7th module of the vancomycin NRPS. For ease of synthesis (Li & Robinson, 2005) , these model peptides contain tyrosine at positions-2 and -6, rather than ß-hydroxy-meta-chlorotyrosine (see Fig. 1 ).
Standard conditions were used for all assays, so that a comparison of turnover efficiencies could be obtained from the extent of linear peptide conversion into the corresponding monocyclic product. The relative amounts of remaining substrate and monocyclic (C-O-D ring) product formed were determined after removal of the peptide from the PCP with hydrazine, and HPLC and ESI-MS analysis of the corresponding peptide-hydrazides (e.g. the hexapeptide hydrazide 3, Fig. 1 ).
The results obtained in assays with vanOxyB and balOxyB are summarized in Table   2 . Intriguingly, all of the electron transfer proteins are able to effectively donate two electrons to vanOxyB during the catalytic cycle, using the hexapeptide-PCP (1) as substrate, with conversions to monocyclic product (3), under the standard conditions, ranging from 60 to over 90%. The heptapeptide-PCP (2, Fig. 1 ), however, is less efficiently converted into the corresponding monocyclic product, with conversions from 10 to 60% observed. It is important, however, to note that this heptapeptide substrate (2) is a mixture of inseparable diastereomers (which arise during the synthesis of the substrate) differing in configuration at C(α) in residue-7. The results also suggest a more favourable interaction between vanOxyB and spinFd or balFd-VII, than between vanOxyB and ecoFld or balFd-V.
Similar findings were made in activity assays using balOxyB. In this case, however, the differences in substrate turnover achieved with the four electron transfer proteins, and between the hexa-and heptapeptide substrates, are more pronounced. Assays with balOxyB and ecoFld or balFd-V showed only marginal turnover of hexapeptide (1) to monocyclic product (3). However, with spinFd and especially with balFd-VII, significant cyclization of the substrate was observed (Table 2) , with conversion of hexapeptide to monocycle similar to that seen in assays with vanOxyB. However, the turnover of heptapeptide (2) was significantly lower, with the best result being 15% conversion to monocyclic product achieved with balFd-VII. These results suggest a higher discrimination between the hexa-and hepta-peptides, with the hexapeptide being more strongly favored as substrate by balOxyB.
Finally, these findings also indicate degeneracy in the ability of various different Fds to support the catalytic activities of P450 coupling enzymes from different glycopeptide producing organisms. This property may well make it difficult to assign a specific function to each of the individual Fds identified in the A. balhimycina genome, at least using in vitro assays. On the other hand, this flexibility should be an advantage in facilitating more detailed in-vitro studies of these interesting cytochrome P450 cross-linking enzymes.
TABLES. Table 2 . Activity assays with van and balOxyB using various electron transfer proteins. The conversions of substrates 1 and 2 (Fig. 1) into the corresponding monocyclic products are shown.
Substrate: 1
Substrate: 2
P450
Reduction system Monocyclic product [a] Monocyclic product [a] spinFd 
